165 related articles for article (PubMed ID: 3293772)
1. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
[No Abstract] [Full Text] [Related]
2. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
Carroll DS; Gralla RJ; Kemeny NE
Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
[No Abstract] [Full Text] [Related]
3. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
[No Abstract] [Full Text] [Related]
4. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of PALA in patients with metastatic lung cancer.
Creagan ET; Eagan RT; Fleming TR; Frytak S; Nichols WC; Ingle JN; Kvols LK
Cancer Treat Rep; 1981; 65(3-4):356-7. PubMed ID: 7237459
[No Abstract] [Full Text] [Related]
6. Phase II study of PALA in advanced large bowel carcinoma.
Rubin J; Purvis J; Britell JC; Hahn RG; Moertel CG; Schutt AJ
Cancer Treat Rep; 1981; 65(3-4):335-6. PubMed ID: 6453645
[No Abstract] [Full Text] [Related]
7. Response of psoriasis to N-phosphonacetyl-L-aspartate.
Earhart RH; DeConti RC; Rubin J; Ohnuma T
Lancet; 1981 Jun; 1(8232):1257-8. PubMed ID: 6112581
[No Abstract] [Full Text] [Related]
8. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ
Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400
[No Abstract] [Full Text] [Related]
10. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Karle JM; Anderson LW; Erlichman C; Cysyk RL
Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
[TBL] [Abstract][Full Text] [Related]
11. Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
Doyle JA; Perry HO; Rubin J; Moertel CG
J Am Acad Dermatol; 1984 Jan; 10(1):21-4. PubMed ID: 6229552
[TBL] [Abstract][Full Text] [Related]
12. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
Kleeberg UR; Mulder JH; Rümke P; Thomas D; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of PALA in lymphoma: an Eastern Cooperative Oncology Group study.
Muggia FM; Tsiatis AA; O'Connell MJ; Glick JH; Opfell RW; Coren A
Cancer Treat Rep; 1984 Mar; 68(3):551-3. PubMed ID: 6231103
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
[TBL] [Abstract][Full Text] [Related]
15. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Johnson RK; Swyryd EA; Stark GR
Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
[No Abstract] [Full Text] [Related]
16. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
Natale RB; Yagoda A; Kelsen DP; Gralla RJ; Watson RC
Cancer Treat Rep; 1982 Dec; 66(12):2091-2. PubMed ID: 7139651
[No Abstract] [Full Text] [Related]
18. Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
Ardalan B; Glazer RI; Kensler TW; Jayaram HN; Van Pham T; Macdonald JS; Cooney DA
Biochem Pharmacol; 1981 Aug; 30(15):2045-9. PubMed ID: 7295324
[No Abstract] [Full Text] [Related]
19. Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.
Hart RD; Ohnuma T; Holland JF
Cancer Treat Rep; 1980; 64(4-5):617-24. PubMed ID: 6448687
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of N-(phosphonacetyl)-L-aspartate.
Erlichman C; Strong JM; Wiernik PH; McAvoy LM; Cohen MH; Levine AS; Hubbard SM; Chabner BA
Cancer Res; 1979 Oct; 39(10):3992-5. PubMed ID: 157801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]